Background Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies,
observational in design, appear to use biased methods that can distort the interaction …

Background Despite the availability of extensive literature on the effect of angiotensin‐
converting enzyme inhibitors (ACEIs)/angiotensin‐receptor blockers (ARBs) on COVID‐19 …

BACKGROUND There is controversy over the effects of angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on the prognosis in patients …

Introduction Despite considerable scientific debate, there have been no prospective clinical
studies on the effects of angiotensin II receptor blockers (ARBs) on the course of COVID-19 …

Among various factors influencing the course of SARS-CoV-2 infection in humans,
macrophage overactivation is considered the main cause of the cytokine storm that leads to …

SARS-CoV-2 infection and its clinical manifestations (COVID-19) quickly evolved to a
pandemic and a global public health emergency. The limited effectivity of available …

This article describes drugs used in primary care that could alter patients' risk for and
severity of COVID-19. The risks and benefits of each drug class were differentiated …

Backgrounds Evidence from several meta-analyses are still controversial about the effects of
angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin-receptor blockers (ARBs) on …

9. Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients with
COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC …

Background: Hypertension is a major risk factor for cardiovascular diseases. Angiotensin
receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) are …